BioSpace News Archive

Drug Development

CG Oncology Touts Bladder Cancer Complete Response Rate for Immunotherapy

Following an upsized IPO earlier this year, CG Oncology on Friday posted promising Phase III data for cretostimogene, which elicited a 75% complete response rate in high-risk non-muscle invasive bladder cancer patients.

May 6, 2024
·
2 min read
·
Tristan Manalac
Drug Development

ASGCT24: Early Trial Results from Freeline, Rocket, Creyon and More

BioSpace will be in attendance at the American Society of Gene & Cell Therapy’s 27th annual meeting, along with thousands of others. Stay with us for updates throughout the week.

May 6, 2024
·
9 min read
·
BioSpace Editorial Staff
Business

BioNTech Misses Q1 Earnings, Revenue on Lower COVID-19 Sales

Reeling from “endemic-level demand” for its COVID-19 vaccine, BioNTech on Monday reported a steep decline in revenues and a loss per share that fell short of analysts’ consensus estimates for the first quarter of 2024.

May 6, 2024
·
2 min read
·
Tristan Manalac
Deals

Novo’s $16.5B Deal with Catalent Gets Another 30 Days Added to FTC Antitrust Review

The Federal Trade Commission has asked for an additional 30 days for its review of Novo Nordisk’s $16.5 billion acquisition of Catalent, with the companies expecting to complete the merger by the end of 2024.

May 6, 2024
·
2 min read
·
Tristan Manalac
Business

Chiesi Inks Potential $486M Deal with Gossamer Bio for Blood Pressure Treatment

The Italian pharma will gain access to Gossamer Bio’s candidate seralutinib, which reached its primary endpoint in a Phase II pulmonary arterial hypertension trial in 2022 and started a Phase III study last year.

May 6, 2024
·
2 min read
·
Tyler Patchen
Employer Resources

Report: The State of Diversity, Equity, Inclusion and Belonging in Life Sciences

BioSpace’s third report on diversity, equity, inclusion and belonging in life sciences examines dramatic shifts in attitude around diversity initiatives.

May 6, 2024
·
1 min read
·
BioSpace Insights
Drug Development

J&J’s ‘Pretzel’ Drug-Device Combo Scores in Mid-Stage Bladder Cancer Study

Following the regulatory victory of Balversa in urothelial carcinoma, Johnson & Johnson on Friday continued its bladder cancer winning streak with an 82.8% complete response rate forTAR-200 in high-risk non-muscle invasive bladder cancer.

May 6, 2024
·
2 min read
·
Tristan Manalac
Drug Development

AstraZeneca Invests $140M in Cellectis, Secures 44% Stake in CAR-T Specialist

Cell and gene therapy company Cellectis announced Monday it has completed a $140 million investment from AstraZeneca that extends the biotech’s cash runway into 2026.

May 6, 2024
·
2 min read
·
Nick Paul Taylor
Business

IRLAB: Invitation to the Interim Report for Q1 2024 Presentation and Webcast

IRLAB Therapeutics AB, a company discovering and developing novel treatments for Parkinson’s disease, announced that the company will hold a presentation in conjunction with the publication of the interim report for the period January-March 2024.

May 6, 2024
·
1 min read
BioCapital

AsclepiX Therapeutics Completes Enrollment in DISCOVER Trial for Neovascular Age-Related Macular Degeneration (nAMD)

AsclepiX Therapeutics, Inc., a clinical-stage biopharmaceutical company leveraging computational biology from Johns Hopkins to identify and develop peptides for improved treatments of retinal diseases, announced the completion of enrollment into the DISCOVER trial.

May 6, 2024
·
2 min read